Dashboard
1
Poor Management Efficiency with a low ROCE of 5.40%
- The company has been able to generate a Return on Capital Employed (avg) of 5.40% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of -0.37% and Operating profit at 2.05% over the last 5 years
4
Flat results in Jun 26
5
With ROE of 5.15%, it has a expensive valuation with a 1.41 Price to Book Value
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.61%
0%
-1.61%
6 Months
-11.71%
0%
-11.71%
1 Year
-43.11%
0%
-43.11%
2 Years
48.49%
0%
48.49%
3 Years
-17.48%
0%
-17.48%
4 Years
30.66%
0%
30.66%
5 Years
-13.87%
0%
-13.87%
Beijing Konruns Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-0.37%
EBIT Growth (5y)
2.05%
EBIT to Interest (avg)
51.01
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.12
Sales to Capital Employed (avg)
0.26
Tax Ratio
11.85%
Dividend Payout Ratio
33.33%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.78%
ROE (avg)
5.07%
Valuation key factors
Factor
Value
P/E Ratio
27
Industry P/E
Price to Book Value
1.41
EV to EBIT
22.45
EV to EBITDA
19.46
EV to Capital Employed
1.48
EV to Sales
4.45
PEG Ratio
0.76
Dividend Yield
NA
ROCE (Latest)
6.58%
ROE (Latest)
5.15%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
247.90
248.90
-0.40%
Operating Profit (PBDIT) excl Other Income
63.70
61.30
3.92%
Interest
2.40
1.40
71.43%
Exceptional Items
2.50
0.50
400.00%
Consolidate Net Profit
52.10
48.20
8.09%
Operating Profit Margin (Excl OI)
215.30%
212.50%
0.28%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is -0.40% vs 22.19% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 8.09% vs 19.31% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
908.70
818.70
10.99%
Operating Profit (PBDIT) excl Other Income
215.70
154.30
39.79%
Interest
7.60
6.20
22.58%
Exceptional Items
-6.30
-106.00
94.06%
Consolidate Net Profit
169.40
21.50
687.91%
Operating Profit Margin (Excl OI)
197.30%
143.30%
5.40%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 10.99% vs -10.44% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 687.91% vs -88.54% in Dec 2024
About Beijing Konruns Pharmaceutical Co., Ltd. 
Beijing Konruns Pharmaceutical Co., Ltd.
Retailing
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






